Healthcare / Drug Manufacturers - Specialty & GenericNSE
$85.90
-6.31 (-6.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $15.3M · quality 34.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
16.9x
↓EV/EBITDA
9.7x
↓ROE
9.3%
↑Gross Margin
43.9%
↓Debt/Equity
1.94
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.7%
FCF CAGR
-56.3%
FCF margin
0.5%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.03B · net income $72.2M · FCF $15.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.03B | $3.03B | $3.39B | $3.02B | $2.80B |
| Net Income | $72.2M | $72.2M | $73.9M | $25.7M | $56.1M |
| EBITDA | $294.5M | $294.5M | $336.0M | $243.7M | $271.0M |
| EPS | 4.56 | 4.56 | 4.96 | 1.67 | 3.79 |
| Gross Margin | 43.9% | 43.9% | 38.7% | 41.6% | 40.0% |
| Operating Margin | 6.5% | 6.5% | 6.4% | 5.8% | 5.4% |
| Net Margin | 2.4% | 2.4% | 2.2% | 0.9% | 2.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.94 | 1.94 | 1.98 | 2.09 | 1.82 |
| Current Ratio | 1.05 | 1.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $15.3M | $15.3M | $118.3M | $-161.8M | $183.3M |
| Returns | |||||
| ROE | 9.3% | 9.3% | 10.3% | 4.0% | 9.6% |
| Valuation | |||||
| P/E | 16.88 | 16.88 | 20.82 | 43.83 | 31.26 |
| EV/EBITDA | 9.66 | 9.66 | 8.94 | 10.11 | 10.37 |
| P/B | 1.76 | 1.76 | 2.26 | 1.80 | 2.99 |
| Growth & Yield | |||||
| Revenue Growth | -10.7% | -10.7% | 12.4% | 7.9% | — |
| EPS Growth | -8.1% | -8.1% | 197.0% | -55.9% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
18.7%
EPS terminal req.
$7.62
Spread vs growth
-26.7%
5Y implied EPS CAGR
15.1%
EPS terminal req.
$9.22
Spread vs growth
-23.2%
10Y implied EPS CAGR
12.5%
EPS terminal req.
$14.85
Spread vs growth
-20.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.7%
Start / end P/E
19.5x → 19.8x
EPS bridge
4.96 → 4.56
Residual
-0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.